Gerulf Hanel

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.

Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.

Journal: The New England journal of medicine

Published: March 04, 2026

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Journal: Transplantation and cellular therapy

Published: January 05, 2026

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

Journal: Leukemia

Published: December 10, 2025

TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.

TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.

Journal: Journal for immunotherapy of cancer

Published: November 17, 2025

FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.

FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.

Journal: Blood advances

Published: August 22, 2025

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

Journal: Blood advances

Published: August 22, 2025

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

Journal: Blood advances

Published: August 22, 2025

Two-layered immune escape in AML is overcome by Fcγ receptor activation and inhibition of PGE2 signaling in NK cells.

Two-layered immune escape in AML is overcome by Fcγ receptor activation and inhibition of PGE2 signaling in NK cells.

Journal: Blood

Published: June 13, 2024

Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study.

Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 18, 2024

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.

Journal: Leukemia

Published: October 21, 2023

Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Journal: Cancer immunology, immunotherapy : CII

Published: May 08, 2023

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Journal: Cancer immunology, immunotherapy : CII

Published: December 18, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026